Jessica Jiyeong Lin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 38 | 2024 | 5223 | 4.340 |
Why?
|
Lung Neoplasms | 52 | 2024 | 13104 | 4.120 |
Why?
|
Protein Kinase Inhibitors | 31 | 2023 | 5534 | 2.350 |
Why?
|
Proto-Oncogene Proteins c-ret | 10 | 2023 | 220 | 1.940 |
Why?
|
Carbazoles | 4 | 2021 | 226 | 1.830 |
Why?
|
Pyrazoles | 14 | 2023 | 1972 | 1.600 |
Why?
|
Protein-Tyrosine Kinases | 10 | 2024 | 2455 | 1.560 |
Why?
|
Drug Resistance, Neoplasm | 15 | 2023 | 5172 | 1.500 |
Why?
|
Receptor Protein-Tyrosine Kinases | 9 | 2023 | 1660 | 1.460 |
Why?
|
Oncogene Proteins, Fusion | 10 | 2022 | 1581 | 1.400 |
Why?
|
Lactams | 7 | 2023 | 156 | 1.330 |
Why?
|
Piperidines | 5 | 2021 | 1602 | 1.240 |
Why?
|
Proto-Oncogene Proteins | 9 | 2024 | 4554 | 1.160 |
Why?
|
Aminopyridines | 8 | 2023 | 542 | 1.110 |
Why?
|
Pyrimidines | 8 | 2023 | 2943 | 1.080 |
Why?
|
Chylous Ascites | 1 | 2022 | 22 | 0.850 |
Why?
|
Chylothorax | 1 | 2022 | 84 | 0.800 |
Why?
|
Lactams, Macrocyclic | 7 | 2023 | 320 | 0.700 |
Why?
|
Platinum | 1 | 2019 | 233 | 0.630 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2023 | 1692 | 0.610 |
Why?
|
Organophosphorus Compounds | 1 | 2018 | 215 | 0.590 |
Why?
|
Genes, erbB-1 | 1 | 2017 | 161 | 0.550 |
Why?
|
Mutation | 23 | 2023 | 29786 | 0.500 |
Why?
|
Protein Kinases | 1 | 2022 | 1640 | 0.490 |
Why?
|
Plasmacytoma | 1 | 2014 | 183 | 0.460 |
Why?
|
Pyridines | 5 | 2023 | 2825 | 0.450 |
Why?
|
Brain Neoplasms | 5 | 2022 | 8861 | 0.430 |
Why?
|
Immunotherapy | 4 | 2020 | 4446 | 0.360 |
Why?
|
Antineoplastic Agents | 6 | 2024 | 13693 | 0.360 |
Why?
|
Gene Fusion | 2 | 2022 | 371 | 0.330 |
Why?
|
Humans | 65 | 2024 | 744366 | 0.300 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2017 | 335 | 0.280 |
Why?
|
Molecular Targeted Therapy | 5 | 2023 | 2725 | 0.270 |
Why?
|
Neoplasm Metastasis | 4 | 2021 | 4851 | 0.250 |
Why?
|
Gene Rearrangement | 2 | 2019 | 1179 | 0.220 |
Why?
|
Solvents | 2 | 2020 | 302 | 0.210 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 252 | 0.200 |
Why?
|
Cancer Vaccines | 2 | 2020 | 1023 | 0.190 |
Why?
|
Acetonitriles | 1 | 2021 | 53 | 0.190 |
Why?
|
Receptor, trkA | 1 | 2021 | 164 | 0.190 |
Why?
|
Aged | 19 | 2022 | 163288 | 0.190 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2021 | 318 | 0.180 |
Why?
|
Middle Aged | 20 | 2022 | 213390 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2021 | 578 | 0.170 |
Why?
|
Amino Acid Substitution | 2 | 2021 | 1793 | 0.170 |
Why?
|
Aged, 80 and over | 12 | 2022 | 57776 | 0.170 |
Why?
|
Adult | 19 | 2022 | 214052 | 0.170 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2017 | 2043 | 0.160 |
Why?
|
MicroRNAs | 1 | 2014 | 3751 | 0.160 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6364 | 0.160 |
Why?
|
Young Adult | 8 | 2022 | 56429 | 0.150 |
Why?
|
Female | 24 | 2022 | 380193 | 0.150 |
Why?
|
Male | 20 | 2022 | 350115 | 0.140 |
Why?
|
Cell Line, Tumor | 9 | 2021 | 16690 | 0.140 |
Why?
|
Acrylamides | 1 | 2018 | 255 | 0.140 |
Why?
|
Oncogene Fusion | 1 | 2017 | 99 | 0.140 |
Why?
|
Retrospective Studies | 9 | 2023 | 77460 | 0.140 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2021 | 1475 | 0.140 |
Why?
|
Genes, erbB-2 | 1 | 2017 | 162 | 0.140 |
Why?
|
Neoplasms | 4 | 2021 | 21696 | 0.140 |
Why?
|
Tyrosine | 1 | 2020 | 1462 | 0.140 |
Why?
|
Gene Amplification | 1 | 2020 | 1063 | 0.130 |
Why?
|
Structure-Activity Relationship | 1 | 2021 | 3130 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2017 | 2504 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 890 | 0.120 |
Why?
|
Family Characteristics | 1 | 2019 | 1000 | 0.120 |
Why?
|
Benzimidazoles | 1 | 2009 | 850 | 0.120 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3595 | 0.120 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2017 | 730 | 0.120 |
Why?
|
Aniline Compounds | 1 | 2018 | 986 | 0.120 |
Why?
|
Lymphocytes | 1 | 2021 | 2617 | 0.110 |
Why?
|
Blood-Brain Barrier | 1 | 2019 | 1019 | 0.110 |
Why?
|
Genetic Heterogeneity | 1 | 2016 | 733 | 0.110 |
Why?
|
Alleles | 2 | 2021 | 6933 | 0.110 |
Why?
|
Quinazolines | 1 | 2018 | 1356 | 0.100 |
Why?
|
Benzamides | 3 | 2022 | 1379 | 0.100 |
Why?
|
Protein Conformation | 1 | 2009 | 4010 | 0.100 |
Why?
|
Models, Molecular | 1 | 2021 | 5451 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3511 | 0.090 |
Why?
|
Piperazines | 1 | 2021 | 2488 | 0.090 |
Why?
|
Melanoma | 4 | 2020 | 5511 | 0.090 |
Why?
|
Indazoles | 2 | 2022 | 290 | 0.090 |
Why?
|
NF-E2-Related Factor 2 | 2 | 2023 | 379 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6489 | 0.080 |
Why?
|
Medical Oncology | 1 | 2021 | 2267 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3721 | 0.080 |
Why?
|
rab GTP-Binding Proteins | 1 | 2010 | 246 | 0.080 |
Why?
|
Biopsy | 1 | 2021 | 6755 | 0.080 |
Why?
|
Thyroid Neoplasms | 1 | 2022 | 2282 | 0.080 |
Why?
|
Microphthalmia-Associated Transcription Factor | 2 | 2010 | 252 | 0.080 |
Why?
|
Treatment Outcome | 5 | 2024 | 63107 | 0.080 |
Why?
|
Janus Kinase 2 | 1 | 2011 | 528 | 0.080 |
Why?
|
GTPase-Activating Proteins | 1 | 2010 | 498 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2019 | 2530 | 0.070 |
Why?
|
STAT3 Transcription Factor | 1 | 2011 | 874 | 0.070 |
Why?
|
Activating Transcription Factor 1 | 1 | 2006 | 26 | 0.070 |
Why?
|
Prognosis | 4 | 2021 | 29060 | 0.070 |
Why?
|
Sarcoma, Clear Cell | 1 | 2006 | 76 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8642 | 0.070 |
Why?
|
RNA-Binding Protein EWS | 1 | 2006 | 216 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10183 | 0.060 |
Why?
|
Animals | 6 | 2019 | 168768 | 0.060 |
Why?
|
Massachusetts | 1 | 2015 | 8662 | 0.050 |
Why?
|
Survival Analysis | 1 | 2015 | 10252 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2010 | 2307 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6773 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11525 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9274 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2022 | 323 | 0.050 |
Why?
|
Breast Neoplasms | 3 | 2015 | 20824 | 0.050 |
Why?
|
Tumor Stem Cell Assay | 1 | 2009 | 118 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18034 | 0.040 |
Why?
|
Nuclear Proteins | 2 | 2023 | 5856 | 0.040 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2009 | 2938 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 629 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 9955 | 0.040 |
Why?
|
Genomic Instability | 1 | 2023 | 695 | 0.040 |
Why?
|
Triazines | 1 | 2021 | 315 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 594 | 0.040 |
Why?
|
Ethylnitrosourea | 1 | 2018 | 51 | 0.040 |
Why?
|
Stem Cells | 1 | 2011 | 3567 | 0.040 |
Why?
|
Mice | 4 | 2019 | 81201 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 861 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20130 | 0.030 |
Why?
|
Brain | 1 | 2023 | 26388 | 0.030 |
Why?
|
Gene Expression Profiling | 4 | 2015 | 9445 | 0.030 |
Why?
|
Mutagenesis | 1 | 2009 | 1264 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 2018 | 401 | 0.030 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2015 | 170 | 0.030 |
Why?
|
Cell Fusion | 1 | 2015 | 297 | 0.030 |
Why?
|
Imidazoles | 1 | 2021 | 1206 | 0.030 |
Why?
|
Ligands | 1 | 2021 | 3282 | 0.030 |
Why?
|
Signal Transduction | 3 | 2011 | 23404 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1364 | 0.030 |
Why?
|
Anticonvulsants | 1 | 2022 | 1916 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1988 | 0.030 |
Why?
|
Transcription Factors | 3 | 2023 | 12207 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6313 | 0.030 |
Why?
|
Transfection | 1 | 2020 | 5895 | 0.030 |
Why?
|
Mutation, Missense | 1 | 2009 | 2566 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 3554 | 0.020 |
Why?
|
Promoter Regions, Genetic | 2 | 2015 | 5867 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6539 | 0.020 |
Why?
|
Epigenomics | 1 | 2015 | 903 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2006 | 9647 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39052 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2460 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2009 | 4805 | 0.020 |
Why?
|
Base Sequence | 1 | 2009 | 12797 | 0.020 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2020 | 2249 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8340 | 0.020 |
Why?
|
Protein Binding | 1 | 2009 | 9384 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5717 | 0.020 |
Why?
|
Melanocyte-Stimulating Hormones | 1 | 2006 | 25 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11031 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 18111 | 0.020 |
Why?
|
SOXE Transcription Factors | 1 | 2006 | 57 | 0.020 |
Why?
|
High Mobility Group Proteins | 1 | 2006 | 187 | 0.020 |
Why?
|
Protein Transport | 1 | 2010 | 1988 | 0.020 |
Why?
|
Adolescent | 2 | 2022 | 85779 | 0.010 |
Why?
|
Child | 2 | 2022 | 77709 | 0.010 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2006 | 315 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8432 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2022 | 9240 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2009 | 1142 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2009 | 3702 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2383 | 0.010 |
Why?
|
Melanocytes | 1 | 2006 | 515 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 8949 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2006 | 2086 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7798 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3505 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2011 | 3203 | 0.010 |
Why?
|
Mice, Nude | 1 | 2006 | 3689 | 0.010 |
Why?
|
Cell Survival | 1 | 2009 | 5882 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 53290 | 0.010 |
Why?
|
Cohort Studies | 1 | 2018 | 40559 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2006 | 10483 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2006 | 11486 | 0.010 |
Why?
|